Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Chubb
Harvard Business School
McKesson
AstraZeneca
Chinese Patent Office
Boehringer Ingelheim
Johnson and Johnson
Citi

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,132,570

« Back to Dashboard

Which drugs does patent 7,132,570 protect, and when does it expire?

Patent 7,132,570 protects NUVIGIL and is included in one NDA.

Protection for NUVIGIL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-eight patent family members in twenty-eight countries.
Summary for Patent: 7,132,570
Title:Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Abstract:The invention relates to a process for the preparation of crystalline forms of the optical enantiomers of modafinil, comprising stages comprising: i) dissolving one of the optical enantiomers of modafinil in a solvent other than ethanol, ii) crystallising the modafinil enantiomer, iii) recovering the crystalline form of the modafinil enantiomer so obtained. The invention also relates to a process for the preparation of the optical enantiomers of modafinil.
Inventor(s): Neckebrock; Olivier (Ponteau Combault, FR), Leproust; Pierre (Creteil, FR)
Assignee: Cephalon France (Maisons-Alfort Cedex, FR)
Application Number:10/539,918
Patent Claim Types:
see list of patent claims
Composition; Process;

Drugs Protected by US Patent 7,132,570

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-001 Jun 15, 2007 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-002 Mar 26, 2009 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-003 Jun 15, 2007 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Cephalon NUVIGIL armodafinil TABLET;ORAL 021875-005 Mar 26, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,132,570

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France02 16412Dec 20, 2002
PCT Information
PCT FiledDecember 18, 2003PCT Application Number:PCT/FR03/03799
PCT Publication Date:July 22, 2004PCT Publication Number: WO20/04/060858

Non-Orange Book US Patents Family Members for Patent 7,132,570

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,382,200 Process for the preparation of and crystalline forms of optical enantiomers of modafinil ➤ Sign Up
8,729,305 Process for the preparation of and crystalline forms of optical enantiomers of modafinil ➤ Sign Up
8,975,442 Process for the preparation of and crystalline forms of optical enantiomers of modafinil ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo
Harvard Business School
Fish and Richardson
Accenture
Cantor Fitzgerald
Merck
Cerilliant
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.